Abstract library

20 results for "Taco".
#1764 Use of Tyrosine-Kinase Inhibitors in Medullary Thyroid Carcinoma: An Institutional Experience
Introduction: Medullary thyroid cancer (MTC) comprises 4% of thyroid tumors. 7-23% of patients (pts) have metastases at diagnosis. In some cases metastatic disease follows an indolent course, and in others it progresses rapidly, requiring systemic treatment. Tyrosine-kinase inhibitors (TKI) have demonstrated a median progression-free survival (PFS) of 11 months.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Medical treatment - Targeted therapies
Presenting Author: Juan Manuel O'Connor
Keywords: TNE, TKI
#1786 Targeted Therapies (TT) (Sunitinib and Everolimus) for Advanced Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET). A Case Series
Introduction: Sunitinib (Sun) and Everolimus (Eve) are effective treatments for advanced GEP-NET. Lack of standard treatment sequencing and potential toxicities may preclude it´s use.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Medical treatment - Targeted therapies
Presenting Author: Juan Manuel O'Connor
Keywords: TNE, therapy target
#51 Epidemiology of the neuroendocrine tumors diagnosed in Cardarelli Hospital: a retrospective single-institution analysis of 274 cases
Introduction: Neuroendocrine tumors (NETs) are considered rare tumors and are characterized by their ability to produce peptides that cause typical hormonal syndromes. Neuroendocrine tumors consist of a wide spectrum of malignancies with different histology that can arise from distributed neuroendocrine cells in the body. Although these tumors are frequently indolent, they can be aggressive and resistant to therapy. Its incidence in the U.S.A has been rising in the last three decades (Surveillance, Epidemiology, and End Results registry). NETs are more common than generally believed.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Ferdinando Riccardi
#271 A Novel Missense Mutation of the TMEM127 Gene that Leads to Pheochromocytoma Phenotype
Introduction: Recently, truncating germline mutations in TMEM127 gene have been identified in 30% of familial cases of adrenal pheochromocytoma (PHEO) and in 3% of apparently sporadic cases.
Conference: 8th Annual ENETS Conference (2011)
Category: Basic
Presenting Author: Rita Domingues
#540 Diagnositc and Prognostic Role of 68GA-DOTATATE PET in Patients with Neuroendocrine Tumors
Introduction: Octreoscan (OS) is currently the gold standard for diagnosis of somatostatin receptor positive NET but it is limited by a lower spatial resolution and physiological uptake noises. DOTATATE is a somatostatin analogue, radiolabelled with 68Ga and adapted for PET imaging.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: DR Francesca Marciello
#673 MEN-1: Difficulties in Diagnosis and Therapeutic Dilemmas
Introduction: MEN1 is rare, and the most common mode of presentation is in previously identified kindred, but may be the propositus of a new kindred or a sporadic case.
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: Basic Science - mTOR and other pathways, signalling, receptors
Presenting Author: Joana Saraiva
Authors: Saraiva J, Santos J, Moreno C, Alves M, ...
#751 Natural History of Resectable Large Cell Neuroendocrine Carcinoma of the Lung
Introduction: Lung large cell neuroendocrine carcinomas (LCNEC) are rare poorly differentiated carcinoma. Their natural history after surgery has been seldom studied.
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: Non digestive NETs (bronchial, MTC, pheochromocytoma)
Presenting Author: Francesca Marciello
#1154 Selective Internal Radiation Therapy (SIRT) Radioembolisation with 90 Yttrium in Patients with Unresectable Liver Neuroendocrine Metastases in a Specialized Center. An Initial Report
Introduction: Most patients with neuroendocrine tumors present liver metastases at some point of the clinical course. Liver directed treatment, such as 90 Yttrium is a method of treatment used in patients with non-resectable liver lesions, which is effective in the control of symptoms and tumor growth.
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: PRRT-Ablative therapies-Endoscopic treatment
Presenting Author: Juan Manuel O'Connor
#1211 Lack of Efficacy of Anthracycline-Containing Second Line Chemotherapy in Patients with GI-NEC After Cisplatin-Based Treatment
Introduction: Little is known about optimal 2nd-line treatment in patients with GI-NEC failing cisplatin-based therapy.
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Medical treatment - Chemotherapy
Presenting Author: Dr. Barbara Kiesewetter
Keywords: GI-NEC
#1481 Neuroendocrine Liver Metastasis: A Novel Nomogram to Predict Patient’s Prognosis After Liver Resection
Introduction: Despite surgery remains the only potentially curative option for patients with neuroendocrine liver metastases (NELMs), the factors determining the prognosis of patients following hepatectomy are poorly understood.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Surgical treatment
Presenting Author: Fabio Bagante